New Stock News | True Biotech Thirds Submissions to Hong Kong Stock Exchange Core Product Azvudine Granted Conditional Approval for Treatment of HIV Infection and COVID-19 in China

According to a report from Zhitong Finance APP, it was disclosed by the Hong Kong Stock Exchange on November 9th that Truebio Biotechnology Limited (referred to as Truebio) has submitted an application to the Hong Kong Stock Exchange Main Board, with CICC being its exclusive sponsor. This is the third time the company has applied for listing on the Hong Kong Stock Exchange, having previously submitted applications on August 4, 2022 and February 18, 2025.